Eagle_Admin, Author at Eagle Pharmaceuticals

Eagle Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)

Posted February 10, 2023

For California Residents: Do Not Sell or Share My Information

page 1 of 5

Cookie Settings

We use cookies to analyze website usage and assist our marketing efforts. Your cookie preference will be stored on your browser, and is categorized as a "Necessary" cookie. Third-party cookies we use to collect website analytics will be stored in your browser only with your consent. You also have the option to opt-out of these cookies using the tool below.

Privacy Policy
Cookie Policy
Notice to California Residents

Necessary

Always Enabled

Necessary cookies store cookie preferences made here in the cookie settings tools.

Cookie	Duration	Description
Cookie Preference	11 months	This cookie is used to store cookie preferences made here in the cookie settings tool.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies provide information about the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
Google Analytics	11 months	A unique identifier given to each browser to track user interactions with the website.

Jeff Lovesy

Christopher Krawtschuk

STEVEN RATOFF

Michael Graves

About

Calo2

byfavo

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance

Eagle Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)

For California Residents: Do Not Sell or Share My Information